Evidence-based dosing of maintenance subcutaneous immunotherapy: A contemporary review of state-of-the-art practice

Hunter Hoover, Bryan Leatherman, Matthew Ryan, Kevin Mcmains, Maria Veling

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Subcutaneous immunotherapy is an effective allergy treatment only if properly dosed. In this article we review the data on the probable effective dose range for subcutaneous immunotherapy and convert the recommended doses into a clinically relevant format. Methods: A comprehensive literature search of dose-response subcutaneous immunotherapy studies was done of EBM databases, Medline database, PreMedline, and the National Guideline Clearinghouse for the period 1980-2016. Recommended doses were converted to the volume of allergen extract that should be added to a 5-mL maintenance vial. Results: A safe and effective dose for subcutaneous immunotherapy is likely 5-20 μg of major allergen per injection. A 0.5-mL injection from a 5-mL maintenance vial containing 0.2 mL of manufacturer's extract of each allergen should reach the lower end of the probable effective dose range for most allergens. A larger volume of extract is required to reach that range when treatment includes cat, dog, or only 1 dust mite. Increasing beyond the commonly prescribed 0.2 mL of manufacturer's extract added to a 5-mL treatment vial is reasonable for nearly all allergens to achieve a maintenance dose higher in the probable effective dose range. Conclusion: Current otolaryngic allergy practice usually escalates patients to 0.5-mL injections from 5-mL maintenance vials containing 0.2 mL of manufacturer's extract of each allergen. With the main exceptions of cat and dog, those injections administered 1 or 2 times per month likely provide an efficacious dose of allergen and are consistent with published guidelines. A larger volume of extract should be considered in certain clinical situations.

Original languageEnglish (US)
JournalInternational Forum of Allergy and Rhinology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Immunotherapy
Allergens
Maintenance
Injections
Hypersensitivity
Cats
Databases
Dogs
Guidelines
Mites
Dust
Therapeutics

Keywords

  • Allergens
  • Allergic rhinitis
  • Cat dander
  • Dog dander
  • Dose response
  • Dust mite
  • Grass pollen
  • Ragweed pollen
  • Subcutaneous immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Evidence-based dosing of maintenance subcutaneous immunotherapy : A contemporary review of state-of-the-art practice. / Hoover, Hunter; Leatherman, Bryan; Ryan, Matthew; Mcmains, Kevin; Veling, Maria.

In: International Forum of Allergy and Rhinology, 01.01.2018.

Research output: Contribution to journalArticle

@article{a9a864b0c12d4b639347b5bc9bc121af,
title = "Evidence-based dosing of maintenance subcutaneous immunotherapy: A contemporary review of state-of-the-art practice",
abstract = "Background: Subcutaneous immunotherapy is an effective allergy treatment only if properly dosed. In this article we review the data on the probable effective dose range for subcutaneous immunotherapy and convert the recommended doses into a clinically relevant format. Methods: A comprehensive literature search of dose-response subcutaneous immunotherapy studies was done of EBM databases, Medline database, PreMedline, and the National Guideline Clearinghouse for the period 1980-2016. Recommended doses were converted to the volume of allergen extract that should be added to a 5-mL maintenance vial. Results: A safe and effective dose for subcutaneous immunotherapy is likely 5-20 μg of major allergen per injection. A 0.5-mL injection from a 5-mL maintenance vial containing 0.2 mL of manufacturer's extract of each allergen should reach the lower end of the probable effective dose range for most allergens. A larger volume of extract is required to reach that range when treatment includes cat, dog, or only 1 dust mite. Increasing beyond the commonly prescribed 0.2 mL of manufacturer's extract added to a 5-mL treatment vial is reasonable for nearly all allergens to achieve a maintenance dose higher in the probable effective dose range. Conclusion: Current otolaryngic allergy practice usually escalates patients to 0.5-mL injections from 5-mL maintenance vials containing 0.2 mL of manufacturer's extract of each allergen. With the main exceptions of cat and dog, those injections administered 1 or 2 times per month likely provide an efficacious dose of allergen and are consistent with published guidelines. A larger volume of extract should be considered in certain clinical situations.",
keywords = "Allergens, Allergic rhinitis, Cat dander, Dog dander, Dose response, Dust mite, Grass pollen, Ragweed pollen, Subcutaneous immunotherapy",
author = "Hunter Hoover and Bryan Leatherman and Matthew Ryan and Kevin Mcmains and Maria Veling",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/alr.22118",
language = "English (US)",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Evidence-based dosing of maintenance subcutaneous immunotherapy

T2 - A contemporary review of state-of-the-art practice

AU - Hoover, Hunter

AU - Leatherman, Bryan

AU - Ryan, Matthew

AU - Mcmains, Kevin

AU - Veling, Maria

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Subcutaneous immunotherapy is an effective allergy treatment only if properly dosed. In this article we review the data on the probable effective dose range for subcutaneous immunotherapy and convert the recommended doses into a clinically relevant format. Methods: A comprehensive literature search of dose-response subcutaneous immunotherapy studies was done of EBM databases, Medline database, PreMedline, and the National Guideline Clearinghouse for the period 1980-2016. Recommended doses were converted to the volume of allergen extract that should be added to a 5-mL maintenance vial. Results: A safe and effective dose for subcutaneous immunotherapy is likely 5-20 μg of major allergen per injection. A 0.5-mL injection from a 5-mL maintenance vial containing 0.2 mL of manufacturer's extract of each allergen should reach the lower end of the probable effective dose range for most allergens. A larger volume of extract is required to reach that range when treatment includes cat, dog, or only 1 dust mite. Increasing beyond the commonly prescribed 0.2 mL of manufacturer's extract added to a 5-mL treatment vial is reasonable for nearly all allergens to achieve a maintenance dose higher in the probable effective dose range. Conclusion: Current otolaryngic allergy practice usually escalates patients to 0.5-mL injections from 5-mL maintenance vials containing 0.2 mL of manufacturer's extract of each allergen. With the main exceptions of cat and dog, those injections administered 1 or 2 times per month likely provide an efficacious dose of allergen and are consistent with published guidelines. A larger volume of extract should be considered in certain clinical situations.

AB - Background: Subcutaneous immunotherapy is an effective allergy treatment only if properly dosed. In this article we review the data on the probable effective dose range for subcutaneous immunotherapy and convert the recommended doses into a clinically relevant format. Methods: A comprehensive literature search of dose-response subcutaneous immunotherapy studies was done of EBM databases, Medline database, PreMedline, and the National Guideline Clearinghouse for the period 1980-2016. Recommended doses were converted to the volume of allergen extract that should be added to a 5-mL maintenance vial. Results: A safe and effective dose for subcutaneous immunotherapy is likely 5-20 μg of major allergen per injection. A 0.5-mL injection from a 5-mL maintenance vial containing 0.2 mL of manufacturer's extract of each allergen should reach the lower end of the probable effective dose range for most allergens. A larger volume of extract is required to reach that range when treatment includes cat, dog, or only 1 dust mite. Increasing beyond the commonly prescribed 0.2 mL of manufacturer's extract added to a 5-mL treatment vial is reasonable for nearly all allergens to achieve a maintenance dose higher in the probable effective dose range. Conclusion: Current otolaryngic allergy practice usually escalates patients to 0.5-mL injections from 5-mL maintenance vials containing 0.2 mL of manufacturer's extract of each allergen. With the main exceptions of cat and dog, those injections administered 1 or 2 times per month likely provide an efficacious dose of allergen and are consistent with published guidelines. A larger volume of extract should be considered in certain clinical situations.

KW - Allergens

KW - Allergic rhinitis

KW - Cat dander

KW - Dog dander

KW - Dose response

KW - Dust mite

KW - Grass pollen

KW - Ragweed pollen

KW - Subcutaneous immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85045092240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045092240&partnerID=8YFLogxK

U2 - 10.1002/alr.22118

DO - 10.1002/alr.22118

M3 - Article

AN - SCOPUS:85045092240

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

ER -